Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Light Therapy for University Students

22 czerwca 2026 zaktualizowane przez: Birna Baldursdottir, Reykjavik University

Effects of Light Therapy on Well-being of University Students: A Pilot Study

The effects of light therapy on well-being among university students was investigated. A three-week intervention study examined whether the use of light glasses improved sleep quality and concentration and reduced symptoms of depression and anxiety among university students. First, a questionnaire was administered to about 130 students to screen for sleep problems. Based on the responses, those with the most sleep problems were invited to participate in the intervention study, which resulted in 39 participants in total. Although studies of light therapy for sleep problems and depression among patients have yielded positive results, the use of light has not been studied much among healthy individuals. The intervention study used glasses that project light in two intensities and participants were randomized into two groups with different intensities of light. The aim of the study was to: a) compare the effects of different light intensities on sleep and concentration and b) investigate whether light therapy influences symptoms of depression and anxiety among university students. The study is expected to increase knowledge of light therapy among healthy individuals, and if the treatment proves successful, it is an easy and inexpensive way to increase well-being among university students.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

39

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Islandia
      • Reykjavik, Islandia, 102
        • Department of Psychology, Reykjavík University

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Being a psychology student at Reykjavik University, Iceland
  • Able to understand, read and write Icelandic
  • At screening assessment prior to the intervention, demonstrating a score of three or above on any of the six items of the BIS scale, thereby including students who showed even mild symptoms of sleep problems

Exclusion Criteria:

  • Not being a psychology student at Reykjavik University, Iceland
  • Not able to understand, read and write Icelandic
  • Demonstrating a score below three on all of the six items of the BIS scale

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Blue Light Therapy
Exposure of experimental circadian-effective blue light (BL) by glasses for 30 minutes each morning during the 3-week intervention
Urządzenie: Light Glasses (Experimental)

The circadian-effective light glasses used by the experimental group (BL) emitted narrowband (peak lambda = 470 nm) blue light with an irradiance of 250 μW/cm2 (120 lux).

The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of regular glasses. For safety purposes, the light glasses do not contain UV or infra-red light.

Brand: AYO glasses.
Aktywny komparator: Dim Light Therapy
Exposure of experimental comparison circadian-ineffective dim light (DL) by glasses for 30 minutes each morning during the 3-week intervention
Urządzenie: Light Glasses (Comparison)

The circadian-ineffective sham glasses (DL) emitted blue light with an irradiance of 2.5 μW/cm2 (1.16 lux).

The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of regular glasses. For safety purposes, the light glasses do not contain UV or infra-red light.

Brand: AYO glasses.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The Bergen Insomnia Scale (BIS)
Ramy czasowe: BIS was used to screen for sleep-related problems, prior to the intervention, at baseline (day 1), at the middle of intervention (FU1, day 11) and at the of intervention (FU2, day 21).
The Bergen Insomnia Scale (BIS) is a short scale on sleep habits consisting of six items pertaining to sleep onset, maintenance, early morning wakening, restorative sleep, daytime functioning, and sleep satisfaction. Responses indicate how often sleep problems, according to the six items, are experienced during the last month on an 8-point scale (0-7 days per week) with a range between 0 and 42, where a higher score suggests more sleep problems.
BIS was used to screen for sleep-related problems, prior to the intervention, at baseline (day 1), at the middle of intervention (FU1, day 11) and at the of intervention (FU2, day 21).
The Pittsburgh Sleep Quality Index (PSQI)
Ramy czasowe: PSQI was administered at baseline (day 1), FU1 (day 11), and FU2 (day 21).
The Pittsburgh Sleep Quality Index (PSQI) consists of 19 self-rated items about sleep habits during the last month. The questions are categorised into seven components, rated from 0 to 3, evaluating sleep duration, quality, and latency as well as habitual sleep efficiency, sleep disturbances, usage of sleep medication, and daytime dysfunction. A global PSQI score, ranging from 0 to 21, is calculated by summarising the seven components' scores, where a higher global score indicates worse sleep quality and a score above five suggests poor sleep quality.
PSQI was administered at baseline (day 1), FU1 (day 11), and FU2 (day 21).
Objective sleep measure by actigraphy: Total time in bed
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Total time in bed, measured as minutes.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Objective sleep measure by actigraphy: Total sleep time
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Total sleep time, measured as minutes.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Objective sleep measure by actigraphy: Sleep latency
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Sleep latency, measured as minutes.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Objective sleep measure by actigraphy: Wake after sleep onset
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Wake after sleep onset, measured as minutes.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Objective sleep measure by actigraphy: Number of awakenings
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Number of awakenings, measured as number of awakenings per sleep period.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Objective sleep measure by actigraphy: Sleep fragmentation index
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Sleep fragmentation index, measured as percentage.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Objective sleep measure by actigraphy: Sleep movement index
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Sleep movement index, measured as events per hour.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Objective sleep measure by actigraphy: Sleep efficiency
Ramy czasowe: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep. Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software. Parameter measured: Sleep efficiency, measured as percentage.
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
The Center for Epidemiological Studies Depression Scale (CES-D)
Ramy czasowe: CES-D was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
The Center for Epidemiological Studies Depression Scale (CES-D) is a 20 item self-report instrument, designed to measure common symptoms of depression that have occurred over the past week such as poor appetite, hopelessness, pessimism, and fatigue. Response options range from 0 to 3 for each item. Scores range from 0 to 60, with high scores indicating greater depressive symptoms.
CES-D was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
General Anxiety Disorder (GAD-7)
Ramy czasowe: GAD-7 was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
General Anxiety Disorder (GAD-7) is a shorter version of the original GAD-13 item scale designed to measure anxiety. Each of the seven questions is rated on a 4-point Likert scale based on symptom frequency. The total score is calculated by summing the scores for all seven items, thus scores range from 0 to 21, with higer score meaning more anxiety. Cut-points are as follows: 0-4: Minimal anxiety, 5-9: Mild anxiety, 10-14: Moderate anxiety, and 15-21: Severe anxiety. A score of 10 or greater is often used as a clinical cut-off point.
GAD-7 was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
The reduced Horne & Östberg Morningness-Eveningness Questionnaire (rMEQ)
Ramy czasowe: rMEQ was administered at baseline (day 1).
The reduced Horne & Östberg Morningness-Eveningness Questionnaire (rMEQ) is a self-report questionnaire is one of the most widely used questionnaire to measure chronotype. The rMEQ consists of 5 questions that assess an individual's preference for morning or evening activities. Based on results from the scoring, individuals can be categorized as: Morning Types: Prefer morning activities; Evening Types: Prefer evening activities or Intermediate Types: Have no strong preference.
rMEQ was administered at baseline (day 1).
The Epworth Sleepiness Scale (ESS)
Ramy czasowe: ESS was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
The Epworth Sleepiness Scale (ESS) is widely used in sleep research and clinical settings and consists of 8 questions (each with 4 answering possibilities) about sleepiness. measure a person's likelihood of dozing off during various daily activities. ESS provides a score ranging from 0 to 24, with higher scores indicating excessive daytime sleepiness. In general ESS scores can be interpreted as follows: 0-5 Lower Normal Daytime Sleepiness; 6-10 Higher Normal Daytime Sleepiness; 11-12 Mild Excessive Daytime Sleepiness; 13-15 Moderate Excessive Daytime Sleepiness; and 16-24 Severe Excessive Daytime Sleepiness.
ESS was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
Objective measures of cognitive performance: Operation Span (Ospan)
Ramy czasowe: Ospan was administered at baseline (day 1) and FU2 (day 21).
Three neuropsychological tests were used to measure cognitive performance: Operation Span (Ospan) is a cognitive task designed to measure working memory capacity by requiring participants to remember sequences of letters while simultaneously solving simple math problems. This dual-task approach assesses how well individuals can manage their memory resources under distraction.
Ospan was administered at baseline (day 1) and FU2 (day 21).
Objective measures of cognitive performance: Digit span forward
Ramy czasowe: Digit span forward was administered at baseline (day 1) and FU2 (day 21).
Three neuropsychological tests were used to measure cognitive performance: Digit span forward is a cognitive task where a person listens to a sequence of numbers and then repeats them back in the same order. This task primarily measures short-term auditory memory and is commonly used in psychological assessments to evaluate working memory capacity.
Digit span forward was administered at baseline (day 1) and FU2 (day 21).
Objective measures of cognitive performance: Digit span backward
Ramy czasowe: Digit span backward was administered at baseline (day 1) and FU2 (day 21).
Three neuropsychological tests were used to measure cognitive performance: Digit span backward is a cognitive task that measures short-term memory by requiring participants to recall a sequence of numbers in reverse order. This task is more challenging than recalling the numbers in the original order, as it involves both storage and manipulation of the information.
Digit span backward was administered at baseline (day 1) and FU2 (day 21).

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Reykjavik University

Współpracownicy

The Icelandic Research Fund

Śledczy

  • Główny śledczy: Birna Baldursdottir, PhD, Reykjavík University, Iceland

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

6 marca 2019

Zakończenie podstawowe (Rzeczywisty)

8 kwietnia 2019

Ukończenie studiów (Rzeczywisty)

8 kwietnia 2019

Daty rejestracji na studia

Pierwszy przesłany

29 maja 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

22 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

25 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

22 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • VSN-19054

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

IPD will be shared upon reasoned requests.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj